<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Ltd pmcid: 717396052716 doi: 10.7554/eLife.52716 : Research Article: Microbiology and" exact="Infectious" post="Disease Multimeric single-domain antibody complexes protect against bunyavirus infections"/>
 <result pre="pmcid: 717396052716 doi: 10.7554/eLife.52716 : Research Article: Microbiology and Infectious" exact="Disease" post="Multimeric single-domain antibody complexes protect against bunyavirus infections Wichgers"/>
 <result pre="and Infectious Disease Multimeric single-domain antibody complexes protect against bunyavirus" exact="infections" post="Wichgers SchreurPaul Jhttps://orcid.org/0000-0001-9790-2438paul.wichgersschreur@wur.nl1van de WaterSandra1HarmsenMichiel1Bermúdez-MéndezErickhttps://orcid.org/0000-0001-9241-789812DrabekDubravka34GrosveldFrank34WernikeKerstinhttps://orcid.org/0000-0001-8071-08275BeerMartin5AebischerAndrea5DaramolaOlalekan6Rodriguez CondeSara6BrennanKaren6KozubDorota6Søndergaard KristiansenMaiken6MistryKieran K6DengZiyan6HellertJan7Guardado-CalvoPablohttp://orcid.org/0000-0001-7292-52707ReyFélix Ahttp://orcid.org/0000-0002-9953-79887van"/>
 <result pre="of bunyavirus biotherapeutics. The method was validated using the zoonotic" exact="Rift Valley fever" post="virus (RVFV) and Schmallenberg virus (SBV), an emerging pathogen"/>
 <result pre="building blocks were assembled into highly potent neutralizing complexes using" exact="bacterial" post="superglue technology. The multimeric complexes were shown to reduce"/>
 <result pre="the vast majority of emerging arboviruses no countermeasures are available." exact="Rift Valley fever" post="virus (RVFV), a phlebovirus within the order Bunyavirales, is"/>
 <result pre="or insufficient countermeasures exist. RVFV is currently confined to the" exact="African" post="continent, the Arabian Peninsula and several islands off the"/>
 <result pre="islands off the coast of Southern Africa, where it causes" exact="recurrent" post="outbreaks (Clark et al., 2018). The world-wide distribution of"/>
 <result pre="severe flu-like symptoms, however a minority of patients may develop" exact="encephalitis" post="or hemorrhagic fever. In addition to members of the"/>
 <result pre="of the family Peribunyaviridae, genus Orthobunyavirus, may also cause severe" exact="disease" post="in humans and animals. In 2011, the incursion of"/>
 <result pre="are capable of spreading very efficiently across new territories. SBV" exact="infections" post="are associated with fever and reduced milk production in"/>
 <result pre="with fever and reduced milk production in cows and severe" exact="malformations" post="in offspring of both large and small ruminants (Hoffmann"/>
 <result pre="moment, no effective antiviral therapy is available to treat bunyavirus" exact="infections" post="in humans. Patients essentially rely on supportive care. Some"/>
 <result pre="obtained with small molecules, mainly nucleoside analogues, that interfere with" exact="viral" post="replication (Gowen and Hickerson, 2017). Recent X-ray crystallography and"/>
 <result pre="are considered the most effective tools to fight (re)emerging life-threatening" exact="viral" post="infections (Jin et al., 2017). A very wide range"/>
 <result pre="considered the most effective tools to fight (re)emerging life-threatening viral" exact="infections" post="(Jin et al., 2017). A very wide range of"/>
 <result pre="a multimeric VHH has shown great promise in counteracting severe" exact="pulmonary disease" post="in infants caused by respiratory syncytial virus (RSV) (Detalle"/>
 <result pre="multimeric VHH has shown great promise in counteracting severe pulmonary" exact="disease" post="in infants caused by respiratory syncytial virus (RSV) (Detalle"/>
 <result pre="promise in counteracting severe pulmonary disease in infants caused by" exact="respiratory" post="syncytial virus (RSV) (Detalle et al., 2016). The therapeutic"/>
 <result pre="form unbreakable isopeptide bonds (Veggiani et al., 2014). The first" exact="bacterial" post="superglue was developed by splitting the immunoglobulin-like collagen adhesion"/>
 <result pre="and SBV-specific VHHs targeting receptor binding glycoprotein domains, and used" exact="bacterial" post="superglues to create virus neutralizing VHH complexes that reduced"/>
 <result pre="presentation of the VHH library construction and phage display selections." exact="Blood" post="lymphocyte RNA was used as a template for VHH-specific"/>
 <result pre="specificity by indirect ELISA and immunoperoxidase monolayer assay (IPMA). In" exact="total" post="62 unique RVFV-Gnecto-specific clones that grouped into 16 CDR"/>
 <result pre="ELISA (Figure 1F,G) and/or were found to bind to fixed" exact="viral" post="antigen in infected cells (Figure 1—figure supplement 2). RVFV"/>
 <result pre="lot of expression plasmids, we used the advantageous properties of" exact="bacterial" post="superglue. VHHs were expressed with Spy- and SnoopTags and"/>
 <result pre="Figure 3. RVFV and SBV-specific neutralization by monovalent VHHs and" exact="bacterial" post="superglue-assembled VHH complexes. (A) RVFV- and (B) SBV-specific monovalent"/>
 <result pre="adding them to susceptible cells. The ND50 values refer to" exact="total" post="VHH per reaction as neutralization might be the result"/>
 <result pre="the llama antibody long hinge region. (D) Illustration of the" exact="bacterial" post="superglue-based site-directed formation of a bispecific or bivalent VHH"/>
 <result pre="a bispecific or bivalent VHH complex. (E) SDS-PAGE of the" exact="bacterial" post="superglue-based formation of bivalent and bispecific VHH complexes using"/>
 <result pre="experiments, selected bivalent and bispecific complexes were evaluated in mouse" exact="infection" post="experiments. To extend the in vivo half-life, the complexes"/>
 <result pre="complex, but also as a result of recycling through the" exact="neonatal" post="Fc receptor (FcRn) (Mehand et al., 2018; Jacobs et"/>
 <result pre="RVFV VHH complex was constructed and evaluated to take the" exact="bacterial" post="superglue approach to the next level and to make"/>
 <result pre="of this trispecific complex we made use of a third" exact="bacterial" post="superglue; SdyTag and SdyCatcher (Veggiani et al., 2014). The"/>
 <result pre="results of the RVFV mouse experiment showed that in the" exact="absence of" post="the ABD domain (RV104-ELP2-RV107) morbidity and mortality could not"/>
 <result pre="none of the surviving animals showed any clinical signs of" exact="disease" post="or significant weight loss. In addition, for all the"/>
 <result pre="weight loss. In addition, for all the antibody treated mice" exact="viral" post="RNA loads in blood and tissue samples were markedly"/>
 <result pre="at medium scale using a Chinese Hamster Ovary (CHO) cell-based" exact="transient" post="expression platform (20 L) in disposable rocking bioreactors (Daramola"/>
 <result pre="VHH-based biotherapeutics hold great promise for the treatment of bunyavirus" exact="infections" post="either prophylactically or therapeutically. Figure 6. Llama-human chimeric antibodies"/>
 <result pre="the threat for human health by including three bunyaviruses; RVFV," exact="Crimean-Congo hemorrhagic fever" post="virus (CCHFV) and severe fever with thrombocytopenia syndrome virus"/>
 <result pre="RVFV, Crimean-Congo hemorrhagic fever virus (CCHFV) and severe fever with" exact="thrombocytopenia" post="syndrome virus (SFTSV), on the Blueprint list of viruses"/>
 <result pre="Crimean-Congo hemorrhagic fever virus (CCHFV) and severe fever with thrombocytopenia" exact="syndrome" post="virus (SFTSV), on the Blueprint list of viruses likely"/>
 <result pre="2018; Allen et al., 2018). For RVFV and SBV, a" exact="limited" post="number of conventional mouse and rabbit mAbs as well"/>
 <result pre="specifically harnessed the advantageous characteristics of VHHs in combination with" exact="bacterial" post="superglues to develop highly potent virus neutralizing complexes. A"/>
 <result pre="results in decreased production yields. Moreover, interference with CDRs is" exact="limited" post="due to the flexibility in positioning of the superglue"/>
 <result pre="not only proven effective in neutralizing viruses, but the presented" exact="bacterial" post="superglue and module-based assembly strategy may also facilitate the"/>
 <result pre="assembly strategy may also facilitate the development of biotherapeutics targeting" exact="cancer" post="and toxins. Interestingly, a related approach primarily based on"/>
 <result pre="complex (Alam et al., 2018). A potential disadvantage of using" exact="bacterial" post="superglues in therapeutics is their intrinsic immunogenicity, leading to"/>
 <result pre="may even reduce efficacy, particularly with successive treatments. Nevertheless, the" exact="bacterial" post="superglue strategy finds its added value, as we showed,"/>
 <result pre="its added value, as we showed, as a very efficient" exact="intermediate" post="step for identification of potent VHH combinations. After optimal"/>
 <result pre="the broad range of receptor and attachment molecules used for" exact="viral" post="attachment and entry in both insect and mammalian cells"/>
 <result pre="these larger complexes were found to reduce or even prevent" exact="virus infection." post="Several mechanisms could explain the higher efficacy of multimeric"/>
 <result pre="interference with receptor binding or interference with fusion through blocking" exact="viral" post="glycoprotein conformational changes. Cross-linking of the glycoproteins may also"/>
 <result pre="class II fusion protein, is responsible for fusion of the" exact="viral" post="membrane with the endosome (Guardado-Calvo et al., 2017; Kielian,"/>
 <result pre="and that these antibodies pose a significant fitness cost for" exact="viral" post="growth. As the biological role of the SBV Gc"/>
 <result pre="the two hIgG1Fc-VHH fusion proteins with the CHO cell based" exact="transient" post="expression platform (Daramola et al., 2014) was efficient and"/>
 <result pre="is expected to provide novel opportunities for the development of" exact="cancer" post="and toxin biotherapeutics. Materials and methods Key resources table"/>
 <result pre="ATCC CRL-3357 Cell line Trichoplusia ni High Five cells Thermo" exact="Fisher" post="Scientific B855-02 Recombinant DNA reagent pRL144 (Harmsen et al.,"/>
 <result pre="al., 2010) Virus-like particles Other Ni-NTA resin Qiagen 30210 Other" exact="Protein" post="A agarose Fast Flow 50% Sigma P3476 Other CHO"/>
 <result pre="Protein A agarose Fast Flow 50% Sigma P3476 Other CHO" exact="transient" post="expression system (Daramola et al., 2014) Expression system Other"/>
 <result pre="al., 2014) Expression system Other Human albumin Sigma A9511 Other" exact="Mouse" post="albumin Sigma A3139 Other Bovine albumin Sigma A7906 Other"/>
 <result pre="Human albumin Sigma A9511 Other Mouse albumin Sigma A3139 Other" exact="Bovine" post="albumin Sigma A7906 Other Bis-Tris NuPAGE Novex Gels Life"/>
 <result pre="Other HRP-conjugated Strep-Tactin IBA 2-1502-001 1:5000 Commercial assay, kit QIAamp" exact="Viral" post="RNA kit Qiagen 52904 Commercial assay, kit RNA Clean"/>
 <result pre="Commercial assay, kit Phusion Flash High-Fidelity PCR Master Mix Thermo" exact="Fisher" post="Scientific F548 Commercial assay, kit MagAttract Virus mini M48"/>
 <result pre="primers ACAGAGCCTCTGAGAAATGTCTG Sequence-based reagent JR830 This paper PCR primers GATTTGCATACCAGTATTGGTG" exact="Antibody" post="Polyclonal HRP-conjugated goat anti-llama IgG-H+L Bethyl A160-100P IPMA (1:1000),"/>
 <result pre="Table 1. Amino acid sequences of used domains and tags." exact="Protein" post="Amino acid sequence SBV Gchead INCKNIQSTQLTIEHLSKCMAFYQNKTSSPVVINEIISDASVDEQELIKSLNLNCNVIDRFISESSVIETQVYYEYIKSQLCPLQVHDIFTINSASNIQWKALARSFTLGVCNTNPHKHICRCLESMQMCTSTKTDHAREMSIYYDGHPDRFEHDMKIILNIMRYIVPGLGRVLLDQIKQTKDYQALRHIQGKLSPKSQSNLQLKGFLEFVDFILGANVTIEKTPQTLTTLSLI Twin Strep-tag GSAWSHPQFEKGGGSGGGSGGSAWSHPQFEK"/>
 <result pre="NL-F6 (Van Der Poel et al., 2014) were obtained after" exact="infections" post="at low multiplicity of infection (0.01) of Vero E6"/>
 <result pre="al., 2014) were obtained after infections at low multiplicity of" exact="infection" post="(0.01) of Vero E6 cells (ATCC CRL-1586, Teddington, United"/>
 <result pre="were mycoplasma free. Llama immunization and phage display selection Two" exact="adult" post="llamas (Lama glama, #9342, #9343) were intramuscularly (hind leg)"/>
 <result pre="repertoire of the individual animals was amplified by RT-PCR from" exact="peripheral" post="blood lymphocytes and inserted into phage display vector pRL144,"/>
 <result pre="instructions, protein productions were initiated in High Five cells (Thermo" exact="Fisher" post="Scientific, Landsmeer, The Netherlands) according to the manufacturer’s instructions."/>
 <result pre="et al., 2016). Production of hIgG1Fc-VHH chimeric antibodies in CHO" exact="transient" post="expression system For medium scale production, the hIgG1Fc-VHH chimeric"/>
 <result pre="production, the hIgG1Fc-VHH chimeric antibodies were expressed in a CHO" exact="transient" post="expression system as previously described (Daramola et al., 2014)."/>
 <result pre="the expression vectors. The clarified harvest supernatant was purified using" exact="Protein" post="A-based chromatography (Liu et al., 2010). SDS-PAGE Samples were"/>
 <result pre="7–10 min at 95°C. Generally, samples containing 2.5–3 µg of" exact="total" post="protein were loaded onto 4–12% or 12% Bis-Tris NuPAGENovex"/>
 <result pre="1:2000 in blocking buffer (100 µl/well) was used as a" exact="secondary" post="antibody (1 hr at RT). For the competition ELISA,"/>
 <result pre="in casein blocking buffer (100 µl/well) was used as a" exact="secondary" post="antibody (1 hr at RT). Immunoperoxidase monolayer assay (IPMA)"/>
 <result pre="in PBS) and incubated for 1 hr at 37°C. Diluted" exact="primary" post="antibodies (VHHs) in blocking buffer (100 µL/well) were added."/>
 <result pre="times with PBST20. Subsequently, a HRP-conjugated goat anti-llama IgG H+L" exact="secondary" post="antibody (Bethyl, A160-100P) in blocking buffer (1:1000, 100 µL/well)"/>
 <result pre="at RT. Titers were calculated as the 50% tissue culture" exact="infective" post="dose (TCID50)/mL using the Spearman-Kärber method. SB10 escape mutant"/>
 <result pre="from the sixth passage exhibiting cytopathic effects were selected for" exact="total" post="RNA isolation using the QIAamp Viral RNA kit (Qiagen)."/>
 <result pre="effects were selected for total RNA isolation using the QIAamp" exact="Viral" post="RNA kit (Qiagen). Isolated RNA was purified and concentrated"/>
 <result pre="total RNA isolation using the QIAamp Viral RNA kit (Qiagen)." exact="Isolated" post="RNA was purified and concentrated using the RNA Clean"/>
 <result pre="neutralization capacity was calculated as ND50. RVFV challenge experiments Six-week-old" exact="female" post="BALB/cAnNCrl mice (Charles River Laboratories) were randomly divided into"/>
 <result pre="were randomly divided into groups of 5 mice, kept in" exact="type III" post="filter-top cages under BSL-3 conditions, and allowed to acclimatize"/>
 <result pre="reaching a humane endpoint. SBV challenge experiments Eighteen male and" exact="female" post="IFNAR-/-mice with a C57BL/6 genetic background (B6.129S2-Ifnar1tm1Agt/Mmjax) were obtained"/>
 <result pre="et al., 2012; Tauscher et al., 2017). For quantification of" exact="viral" post="RNA, an external SBV standard was included. Statistical analyses"/>
 <result pre="Tauscher et al., 2017). For quantification of viral RNA, an" exact="external" post="SBV standard was included. Statistical analyses When appropriate, data"/>
 <result pre="RVFV challenge experiments) or German Law on Animal Experiments (SBV" exact="infection" post="experiment). Permissions were granted by the Dutch Central Authority"/>
 <result pre="Experiments (SBV infection experiment). Permissions were granted by the Dutch" exact="Central" post="Authority for Scientific Procedures on Animals (AVD401002016725) and the"/>
 <result pre="antibody targets a site of vulnerability on the surface of" exact="Rift Valley fever" post="virusCell Reports253750375810.1016/j.celrep.2018.12.00130590046 Arbabi-GhahroudiM2017Camelid Single-Domain antibodies: historical perspective and future"/>
 <result pre="antibodies as antitumor therapeuticsFrontiers in Immunology8160310.3389/fimmu.2017.0160329213270 BesselaarTGBlackburnNK1992The synergistic neutralization of" exact="Rift Valley fever" post="virus by monoclonal antibodies to the envelope glycoproteinsArchives of"/>
 <result pre="curious tripodal glycoprotein spikePLOS Pathogens9e100337410.1371/journal.ppat.100337423696739 ClarkMHAWarimweGMDi NardoALyonsNAGubbinsS2018Systematic literature review of" exact="Rift Valley fever" post="virus seroprevalence in Livestock, wildlife and humans in Africa"/>
 <result pre="from 1968 to 2016PLOS Neglected Tropical Diseases12e000662710.1371/journal.pntd.000662730036382 DaramolaOStevensonJDeanGHattonDPettmanGHolmesWFieldR2014A high-yielding CHO" exact="transient" post="system: coexpression of genes encoding EBNA-1 and GS enhances"/>
 <result pre="transient system: coexpression of genes encoding EBNA-1 and GS enhances" exact="transient" post="protein expressionBiotechnology Progress3013214110.1002/btpr.180924106171 de BoerSMKortekaasJAntonisAFKantJvan OplooJLRottierPJMoormannRJBoschBJ2010Rift Valley fever virus"/>
 <result pre="Progress3013214110.1002/btpr.180924106171 de BoerSMKortekaasJAntonisAFKantJvan OplooJLRottierPJMoormannRJBoschBJ2010Rift Valley fever virus subunit vaccines confer" exact="complete" post="protection against a lethal virus challengeVaccine282330233910.1016/j.vaccine.2009.12.06220056185 De VliegerDBallegeerMRosseyISchepensBSaelensX2018Single-Domain antibodies"/>
 <result pre="virus challengeVaccine282330233910.1016/j.vaccine.2009.12.06220056185 De VliegerDBallegeerMRosseyISchepensBSaelensX2018Single-Domain antibodies and their formatting to combat" exact="viral" post="infectionsAntibodies8110.3390/antib8010001 DekkersGBentlageAEHStegmannTCHowieHLLissenberg-ThunnissenSZimringJRispensTVidarssonG2017Affinity of human IgG subclasses to mouse fc"/>
 <result pre="ALX-0171, a potent novel therapeutic nanobody for the treatment of" exact="respiratory" post="syncytial virus infectionAntimicrobial Agents and Chemotherapy6061310.1128/AAC.01802-1526438495 DrabekDJanssensRde BoerERademakerRKloessJSkehelJGrosveldF2016Expression cloning"/>
 <result pre="mutation 'hot spot' in the Schmallenberg virus M segmentJournal of" exact="General" post="Virology941161116710.1099/vir.0.049908-023364189 GahnTASugdenB1995An EBNA-1-dependent enhancer acts from a distance of"/>
 <result pre="Virology692633263610.1128/JVI.69.4.2633-2636.19957884916 GolenderNBrennerJValdmanMKhinichYBumbarovVPanshinAEderyNPismanikSBeharA2015Malformations caused by Shuni virus in ruminants, Israel, 2014-2015Emerging" exact="Infectious" post="Diseases212267226810.3201/eid2112.15080426583957 Gonzalez-SapienzaGRossottiMATabares-da RosaS2017Single-Domain antibodies as versatile affinity reagents for"/>
 <result pre="LamballerieX2017Emerging arboviruses: why today?One Health411310.1016/j.onehlt.2017.06.00128785601 GowenBBHickersonBT2017Hemorrhagic fever of Bunyavirus etiology:" exact="disease" post="models and progress towards new therapiesJournal of Microbiology5518319510.1007/s12275-017-7029-8 Guardado-CalvoPAtkovskaKJeffersSAGrauNBackovicMPérez-VargasJde"/>
 <result pre="protein drives target membrane insertionScience35866366710.1126/science.aal271229097548 HalldorssonSLiSLiMHarlosKBowdenTAHuiskonenJT2018Shielding and activation of a" exact="viral" post="membrane fusion proteinNature Communications934910.1038/s41467-017-02789-229367607 HarmsenMMRuulsRCNijmanIJNiewoldTAFrenkenLGde GeusB2000Llama heavy-chain V regions"/>
 <result pre="by neutralizing antibodiesNature Communications1087910.1038/s41467-019-08832-830787296 HoffmannBScheuchMHöperDJungblutRHolstegMSchirrmeierHEschbaumerMGollerKVWernikeKFischerMBreithauptAMettenleiterTCBeerM2012Novel Orthobunyavirus in cattle, Europe, 2011Emerging" exact="Infectious" post="Diseases1846947210.3201/eid1803.11190522376991 HuiskonenJTOverbyAKWeberFGrünewaldK2009Electron cryo-microscopy and single-particle averaging of Rift Valley"/>
 <result pre="Europe, 2011Emerging Infectious Diseases1846947210.3201/eid1803.11190522376991 HuiskonenJTOverbyAKWeberFGrünewaldK2009Electron cryo-microscopy and single-particle averaging of" exact="Rift Valley fever" post="virus: evidence for Gn-Gc glycoprotein heterodimersJournal of Virology833762376910.1128/JVI.02483-0819193794 HulstMKortekaasJHakze-van"/>
 <result pre="Virology833762376910.1128/JVI.02483-0819193794 HulstMKortekaasJHakze-van der HoningRVastenhouwSCornellissenJvan MaanenKBossersAHardersFStockhofeNvan der PoelW2013Genetic characterization of an" exact="atypical" post="Schmallenberg virus isolated from the brain of a malformed"/>
 <result pre="ONE6e1766510.1371/journal.pone.001766521483777 IezziMEPolicastroLWerbajhSPodhajcerOCanzianiGA2018Single-Domain antibodies and the promise of modular targeting in" exact="Cancer" post="imaging and treatmentFrontiers in Immunology927310.3389/fimmu.2018.0027329520274 JacobsSAGibbsACConkMYiFMaguireDKaneCO'NeilKT2015Fusion to a highly"/>
 <result pre="Cancer imaging and treatmentFrontiers in Immunology927310.3389/fimmu.2018.0027329520274 JacobsSAGibbsACConkMYiFMaguireDKaneCO'NeilKT2015Fusion to a highly" exact="stable" post="consensus albumin binding domain allows for tunable pharmacokineticsProtein Engineering"/>
 <result pre="proteinsVirology344384710.1016/j.virol.2005.09.03616364734 KortekaasJDekkerAde BoerSMWeerdmeesterKVloetRPde WitAAPeetersBPMoormannRJ2010Intramuscular inoculation of calves with an experimental" exact="Newcastle disease" post="virus-based vector vaccine elicits neutralizing antibodies against Rift Valley"/>
 <result pre="KortekaasJDekkerAde BoerSMWeerdmeesterKVloetRPde WitAAPeetersBPMoormannRJ2010Intramuscular inoculation of calves with an experimental Newcastle" exact="disease" post="virus-based vector vaccine elicits neutralizing antibodies against Rift Valley"/>
 <result pre="experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against" exact="Rift Valley fever" post="virusVaccine282271227610.1016/j.vaccine.2010.01.00120079874 KortekaasJOreshkovaNCobos-JiménezVVloetRPPotgieterCAMoormannRJ2011Creation of a nonspreading Rift Valley fever virusJournal"/>
 <result pre="antibodies against Rift Valley fever virusVaccine282271227610.1016/j.vaccine.2010.01.00120079874 KortekaasJOreshkovaNCobos-JiménezVVloetRPPotgieterCAMoormannRJ2011Creation of a nonspreading" exact="Rift Valley fever" post="virusJournal of Virology85126221263010.1128/JVI.00841-1121957302 KortekaasJAntonisAFKantJVloetRPVogelAOreshkovaNde BoerSMBoschBJMoormannRJ2012Efficacy of three candidate Rift"/>
 <result pre="Valley fever virusJournal of Virology85126221263010.1128/JVI.00841-1121957302 KortekaasJAntonisAFKantJVloetRPVogelAOreshkovaNde BoerSMBoschBJMoormannRJ2012Efficacy of three candidate" exact="Rift Valley fever" post="vaccines in sheepVaccine303423342910.1016/j.vaccine.2012.03.02722449427 LaventieBJRademakerHJSalehMde BoerEJanssensRBourcierTSubiliaAMarcellinLvan HaperenRLebbinkJHChenTPrévostGGrosveldFDrabekD2011Heavy chain-only antibodies and"/>
 <result pre="herdsActa Veterinaria Scandinavica544410.1186/1751-0147-54-4422871162 MehandMSMillettPAl-ShorbajiFRothCKienyMPMurgueB2018World health organization methodology to prioritize emerging" exact="infectious diseases" post="in need of research and developmentEmerging Infectious Diseases2417142710.3201/eid2409.171427 MullerRSaluzzoJFLopezNDreierTTurellMSmithJBouloyM1995Characterization"/>
 <result pre="prioritize emerging infectious diseases in need of research and developmentEmerging" exact="Infectious" post="Diseases2417142710.3201/eid2409.171427 MullerRSaluzzoJFLopezNDreierTTurellMSmithJBouloyM1995Characterization of Clone 13, a naturally attenuated avirulent"/>
 <result pre="MullerRSaluzzoJFLopezNDreierTTurellMSmithJBouloyM1995Characterization of Clone 13, a naturally attenuated avirulent isolate of" exact="Rift Valley fever" post="virus, which is altered in the small segmentThe American"/>
 <result pre="Valley fever virus, which is altered in the small segmentThe" exact="American" post="Journal of Tropical Medicine and Hygiene5340541110.4269/ajtmh.1995.53.4057485695 MuyldermansS2013Nanobodies: natural single-domain"/>
 <result pre="virus: disulfide bonding and structural determinants of neutralizationThe Journal of" exact="General" post="Virology981259127310.1099/jgv.0.00081028640745 ShermanMBFreibergANHolbrookMRWatowichSJ2009Single-particle cryo-electron microscopy of Rift Valley fever virusVirology387111510.1016/j.virol.2009.02.03819304307"/>
 <result pre="of neutralizationThe Journal of General Virology981259127310.1099/jgv.0.00081028640745 ShermanMBFreibergANHolbrookMRWatowichSJ2009Single-particle cryo-electron microscopy of" exact="Rift Valley fever" post="virusVirology387111510.1016/j.virol.2009.02.03819304307 TanLLHoonSSWongFT2016Kinetic controlled Tag-Catcher interactions for directed covalent protein"/>
 <result pre="directed covalent protein assemblyPLOS ONE11e016507410.1371/journal.pone.016507427783674 TauscherKWernikeKFischerMWegeltAHoffmannBTeifkeJPBeerM2017Characterization of Simbu serogroup virus" exact="infections" post="in type I interferon receptor knock-out miceArchives of Virology1623119312910.1007/s00705-017-3475-128702933"/>
 <result pre="protein assemblyPLOS ONE11e016507410.1371/journal.pone.016507427783674 TauscherKWernikeKFischerMWegeltAHoffmannBTeifkeJPBeerM2017Characterization of Simbu serogroup virus infections in" exact="type I" post="interferon receptor knock-out miceArchives of Virology1623119312910.1007/s00705-017-3475-128702933 TraenkleBRothbauerU2017Under the microscope:"/>
 <result pre="microscopyFrontiers in Immunology8103010.3389/fimmu.2017.0103028883823 van den BromRLuttikholtSJLievaart-PetersonKPeperkampNHMarsMHvan der PoelWHVellemaP2012Epizootic of ovine" exact="congenital" post="malformations associated with Schmallenberg virus infectionTijdschrift Voor Diergeneeskunde13710611122393844 Van"/>
 <result pre="in Immunology8103010.3389/fimmu.2017.0103028883823 van den BromRLuttikholtSJLievaart-PetersonKPeperkampNHMarsMHvan der PoelWHVellemaP2012Epizootic of ovine congenital" exact="malformations" post="associated with Schmallenberg virus infectionTijdschrift Voor Diergeneeskunde13710611122393844 Van Der"/>
 <result pre="PoelWHParlevlietJMVerstratenERKooiEAHakze-Van Der HoningRStockhofeN2014Schmallenberg virus detection in bovine semen after experimental" exact="infection" post="of bullsEpidemiology and Infection1421495150010.1017/S095026881300257424103399 van EedenCWilliamsJHGerdesTGvan WilpeEViljoenASwanepoelRVenterM2012Shuni virus as"/>
 <result pre="bullsEpidemiology and Infection1421495150010.1017/S095026881300257424103399 van EedenCWilliamsJHGerdesTGvan WilpeEViljoenASwanepoelRVenterM2012Shuni virus as cause of" exact="neurologic disease" post="in horsesEmerging Infectious Diseases1831832110.3201/eid1802.11140322305525 van EedenCHardersFKortekaasJBossersAVenterM2014Genomic and phylogenetic characterization"/>
 <result pre="and Infection1421495150010.1017/S095026881300257424103399 van EedenCWilliamsJHGerdesTGvan WilpeEViljoenASwanepoelRVenterM2012Shuni virus as cause of neurologic" exact="disease" post="in horsesEmerging Infectious Diseases1831832110.3201/eid1802.11140322305525 van EedenCHardersFKortekaasJBossersAVenterM2014Genomic and phylogenetic characterization"/>
 <result pre="EedenCWilliamsJHGerdesTGvan WilpeEViljoenASwanepoelRVenterM2012Shuni virus as cause of neurologic disease in horsesEmerging" exact="Infectious" post="Diseases1831832110.3201/eid1802.11140322305525 van EedenCHardersFKortekaasJBossersAVenterM2014Genomic and phylogenetic characterization of Shuni virusArchives"/>
 <result pre="functionsFrontiers in Immunology552010.3389/fimmu.2014.0052025368619 WangQMaTWuYChenZZengHTongZGaoFQiJZhaoZChaiYYangHWongGBiYWuLShiRYangMSongJJiangHAnZWangJYilmaTDShiYLiuWJLiangMQinCGaoGFYanJ2019Neutralization mechanism of human monoclonal antibodies against" exact="Rift Valley fever" post="virusNature Microbiology41231124110.1038/s41564-019-0411-z30936489 WernikeKBreithauptAKellerMHoffmannBBeerMEschbaumerM2012Schmallenberg virus infection of adult type I"/>
 <result pre="human monoclonal antibodies against Rift Valley fever virusNature Microbiology41231124110.1038/s41564-019-0411-z30936489 WernikeKBreithauptAKellerMHoffmannBBeerMEschbaumerM2012Schmallenberg" exact="virus infection" post="of adult type I interferon receptor knock-out micePLOS ONE7e4038010.1371/journal.pone.004038022792298"/>
 <result pre="monoclonal antibodies against Rift Valley fever virusNature Microbiology41231124110.1038/s41564-019-0411-z30936489 WernikeKBreithauptAKellerMHoffmannBBeerMEschbaumerM2012Schmallenberg virus" exact="infection" post="of adult type I interferon receptor knock-out micePLOS ONE7e4038010.1371/journal.pone.004038022792298"/>
 <result pre="against Rift Valley fever virusNature Microbiology41231124110.1038/s41564-019-0411-z30936489 WernikeKBreithauptAKellerMHoffmannBBeerMEschbaumerM2012Schmallenberg virus infection of" exact="adult" post="type I interferon receptor knock-out micePLOS ONE7e4038010.1371/journal.pone.004038022792298 WernikeKBrocchiECordioliPSénéchalYSchelpCWegeltAAebischerARoman-SosaGReimannIBeerM2015aA novel"/>
 <result pre="Rift Valley fever virusNature Microbiology41231124110.1038/s41564-019-0411-z30936489 WernikeKBreithauptAKellerMHoffmannBBeerMEschbaumerM2012Schmallenberg virus infection of adult" exact="type I" post="interferon receptor knock-out micePLOS ONE7e4038010.1371/journal.pone.004038022792298 WernikeKBrocchiECordioliPSénéchalYSchelpCWegeltAAebischerARoman-SosaGReimannIBeerM2015aA novel panel of"/>
 <result pre="and reveals antigenic differencesVeterinary Research462710.1186/s13567-015-0165-425889366 WernikeKHoffmannBConrathsFJBeerM2015bSchmallenberg virus recurrence, Germany, 2014Emerging" exact="Infectious" post="Diseases211202120410.3201/eid2107.15018026079975 WernikeKAebischerARoman-SosaGBeerM2017The N-terminal domain of Schmallenberg virus envelope protein"/>
 <result pre="infectionScientific Reports74250010.1038/srep4250028211908 Wichgers SchreurPJPaweskaJTKantJKortekaasJ2017A novel highly sensitive, rapid and safe" exact="Rift Valley fever" post="virus neutralization testJournal of Virological Methods248263010.1016/j.jviromet.2017.06.00128583857 WuYJiangSYingT2017aSingle-Domain antibodies as"/>
 <result pre="testJournal of Virological Methods248263010.1016/j.jviromet.2017.06.00128583857 WuYJiangSYingT2017aSingle-Domain antibodies as therapeutics against human" exact="viral" post="diseasesFrontiers in Immunology8180210.3389/fimmu.2017.0180229326699 WuYZhuYGaoFJiaoYOladejoBOChaiYBiYLuSDongMZhangCHuangGWongGLiNZhangYLiYFengWHShiYLiangMZhangRQiJGaoGF2017bStructures of Phlebovirus glycoprotein Gn and"/>
 <result pre="a rapid covalent bond to a protein, through engineering a" exact="bacterial" post="adhesinPNAS109E690E69710.1073/pnas.111548510922366317"/>
</results>
